Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase
2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal
Disease Activity in Patients with Active Psoriatic Arthritis:
Results from a Randomized Phase 2b Study

a 2024

Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study

GOTTLIEB, Alice; Elena MUENSTERMAN; Alan KIVITZ; Eva DOKOUPILOVÁ; Apinya LERTRATANAKUL et al.

Základní údaje

Originální název

Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study

Autoři

GOTTLIEB, Alice; Elena MUENSTERMAN; Alan KIVITZ; Eva DOKOUPILOVÁ; Apinya LERTRATANAKUL; Ting HONG; Jingjing CHEN a Xenofon BARALIAKOS

Vydání

2024

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30226 Rheumatology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14160/24:00139088

Organizační jednotka

Farmaceutická fakulta

UT WoS

001331419104213

Klíčová slova anglicky

Disease Activity; Psoriatic arthritis; Randomized Trial

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam

Změněno: 17. 3. 2025 11:50, Ing. Richard Heger, Ph.D.

Anotace

V originále

Zasocitinib (TAK-279) is a highly selective, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial in patients with active psoriatic arthritis (PsA; NCT05153148), significantly more patients treated with zasocitinib achieved ACR20 responses at Week 12 than with placebo (15 mg [53.3%], 30 mg [54.2%], placebo [29.2%]; p = 0.002).1 Here, additional data on skin and overall disease activity are presented.

Citovat

GOTTLIEB, Alice; Elena MUENSTERMAN; Alan KIVITZ; Eva DOKOUPILOVÁ; Apinya LERTRATANAKUL; Ting HONG; Jingjing CHEN a Xenofon BARALIAKOS. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study. 2024.

@proceedings{2484700,
   author = {Gottlieb, Alice and Muensterman, Elena and Kivitz, Alan and Dokoupilová, Eva and Lertratanakul, Apinya and Hong, Ting and Chen, Jingjing and Baraliakos, Xenofon},
   keywords = {Disease Activity; Psoriatic arthritis; Randomized Trial},
   language = {eng},
   title = {Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study},
   url = {https://www.webofscience.com/wos/woscc/full-record/WOS:001331419104213},
   year = {2024}
}

TY  - CONF
ID  - 2484700
AU  - Gottlieb, Alice - Muensterman, Elena - Kivitz, Alan - Dokoupilová, Eva - Lertratanakul, Apinya - Hong, Ting - Chen, Jingjing - Baraliakos, Xenofon
PY  - 2024
TI  - Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
KW  - Disease Activity
KW  - Psoriatic arthritis
KW  - Randomized Trial
UR  - https://www.webofscience.com/wos/woscc/full-record/WOS:001331419104213
N2  - Zasocitinib (TAK-279) is a highly selective, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial in patients with active psoriatic arthritis (PsA; NCT05153148), significantly more patients treated with zasocitinib achieved ACR20 responses at Week 12 than with placebo (15 mg [53.3%], 30 mg [54.2%], placebo [29.2%]; p = 0.002).1 Here, additional data on skin and overall disease activity are presented.
ER  -

GOTTLIEB, Alice; Elena MUENSTERMAN; Alan KIVITZ; Eva DOKOUPILOVÁ; Apinya LERTRATANAKUL; Ting HONG; Jingjing CHEN a Xenofon BARALIAKOS. \textit{Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study}. 2024.

Přehled o publikaci